#$%^&*AU2013202896A120130502.pdf#####HAninecnvoven\kNRPortbl\DCC\AAR\5058K93 I.DOC-5tM)2013 Abstract The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density a method of ameliorating the effects of an osteoclast-related disorder a method of treating a bone-related disorder by maintaining bone density and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcaemia or hypercalcaemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphophonate is contraindicated. 37a
